Gaucher Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Gaucher Disease stocks.

Gaucher Disease Stocks Recent News

Date Stock Title
Nov 20 SNY CDC warns of an imminent spike in COVID, flu cases
Nov 20 SNY Here’s What Drove Sanofi’s (SNY) Earnings
Nov 20 SNY Sanofi: Information concerning the total number of voting rights and shares - October 2024
Nov 19 FOLD HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Nov 18 SNY FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 15 SNY How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 SNY FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
Nov 15 SNY Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
Nov 15 SNY Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk
Nov 15 PLX PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
Nov 15 SNY Trump’s RFK Jr. Pick Weighs on Vaccine Makers
Nov 15 SNY Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
Nov 15 SNY European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Nov 15 SNY EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Nov 15 SNY Drugmaker stocks slide as Trump picks vaccine sceptic RFK Jr for US health job
Nov 15 PLX Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
Nov 15 SNY Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Nov 15 SNY Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Nov 15 SNY Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Nov 14 SNY Vaccine makers close lower amid reports RFK Jr may head HHS (update)
Gaucher Disease

Gaucher's disease or Gaucher disease () (GD) is a genetic disorder in which glucocerebroside (a sphingolipid, also known as glucosylceramide) accumulates in cells and certain organs. The disorder is characterized by bruising, fatigue, anemia, low blood platelet count and enlargement of the liver and spleen, and is caused by a hereditary deficiency of the enzyme glucocerebrosidase (also known as glucosylceramidase), which acts on glucocerebroside. When the enzyme is defective, glucocerebroside accumulates, particularly in white blood cells and especially in macrophages (mononuclear leukocytes). Glucocerebroside can collect in the spleen, liver, kidneys, lungs, brain, and bone marrow.
Manifestations may include enlarged spleen and liver, liver malfunction, skeletal disorders or bone lesions that may be painful, severe neurological complications, swelling of lymph nodes and (occasionally) adjacent joints, distended abdomen, a brownish tint to the skin, anemia, low blood platelet count, and yellow fatty deposits on the white of the eye (sclera). Persons seriously affected may also be more susceptible to infection. Some forms of Gaucher's disease may be treated with enzyme replacement therapy.
The disease is caused by a recessive mutation in the GBA gene located on chromosome 1 and affects both males and females. About one in 100 people in the United States are carriers of the most common type of Gaucher disease. The carrier rate among Ashkenazi Jews is 8.9% while the birth incidence is one in 450.Gaucher's disease is the most common of the lysosomal storage diseases. It is a form of sphingolipidosis (a subgroup of lysosomal storage diseases), as it involves dysfunctional metabolism of sphingolipids.The disease is named after the French physician Philippe Gaucher, who originally described it in 1882.

Browse All Tags